Holdings
Concentrating on products that are leaders in their therapeutic class, Royalty Pharma’s products generated over $10.4 billion in worldwide sales in 2006 and are well diversified across product and therapeutic classes. In addition to the diversified and predictable revenue streams provided by the Company’s marketed products, Royalty Pharma expects further revenue growth and diversification from its four products in late stage clinical development.